Joflupaan (123i) Rotop

Ioflupane, the active ingredient in Joflupaan (123i) Rotop, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed to evaluate Parkinsonian syndromes and other movement disorders by visualising dopaminergic neuron integrity in adult patients.

GNH USA supplies Joflupaan (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Joflupaan (123i) Rotop is used in diagnostic imaging of the dopaminergic system, helping clinicians assess movement‑disorder conditions. - Parkinsonian syndromes: enables visualization of presynaptic dopamine transporter loss to support diagnosis. - Differential diagnosis of movement disorders: distinguishes Parkinson’s disease from atypical parkinsonism and essential tremor. - Evaluation of dopaminergic neuron integrity: provides quantitative SPECT data on neuronal viability for research and clinical monitoring.

Adverse reactions may occur following intravenous administration of Ioflupane. Most are mild and transient, but rare serious events have been reported.

Common Side Effects: - Nausea: mild, self‑limiting. - Headache: transient, resolves without intervention. - Injection site pain: brief discomfort at the venipuncture site. - Dizziness: usually short‑lived. - Transient hypotension: mild blood‑pressure drop. - Flushing: brief skin reddening.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical care. - Severe hypotension: marked blood‑pressure reduction needing monitoring. - Pulmonary edema: fluid accumulation in lungs, rare but serious. - Seizures: occasional neurologic event. - Severe arrhythmia: cardiac rhythm disturbances. - Radiation‑induced tissue injury: unlikely but possible with high cumulative exposure.

Prior to administration, clinicians should evaluate patient history and specific risk factors. - Pregnancy: unknown safety; avoid unless essential. - Breastfeeding: unknown; consider discontinuation during treatment. - Renal impairment: assess kidney function, as excretion may be altered. - Known hypersensitivity to Ioflupane or similar compounds: contraindicated. - Concomitant dopamine‑affecting drugs: may interfere with imaging results. - Store at ambient temperature: keep in original container, protect from moisture and light.

Ioflupane may interact with other agents that influence dopamine transport or imaging quality.

Major Interactions (Avoid): - Other DAT‑targeting radiopharmaceuticals: competitive binding reduces image accuracy. - Cocaine or amphetamine use: blocks DAT, leading to false‑negative scans. - High‑dose dopamine agonists: may alter tracer distribution. - Radiopharmaceuticals with overlapping emission spectra: interfere with SPECT interpretation. - Strong MAO‑B inhibitors: potential pharmacodynamic interference.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive hypotensive effect. - Sedatives or anxiolytics: may mask transient dizziness. - Anti‑emetics: could mask nausea related to the tracer. - Anticholinergic drugs: may affect central nervous system imaging patterns. - Contrast agents used in other imaging studies: schedule appropriately to avoid signal overlap.